NASDAQ
154.04USD
-4.03 (-2.55%)
We have scored 76 news catalysts on Moderna, Inc. (MRNA) over the past 12 months. The biggest single-day move next to one of them came Aug 20, 2026, when MRNA closed −23.5%: “Moderna Stock Rockets Higher After Positive Cancer Vaccine Trial Data”. Coverage across the window leans positive (average ticker sentiment +0.37). Most of the impact sits in sector healthcare and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
61.1B
P/E
—
EPS
—
Beta
0.90
52W range
22.28-176.66
Day range
150.26–159.79
Open
158.35
Prev close
158.07
Volume
20.2M
Avg volume
13.4M
Dividend
0.00
IPO
2018-12-07
Analysts publish price targets on MRNA, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
13 analyst price targets from $25 to $245
as of 2026-09-11
The market is 14% above the median target — more optimistic than the analysts.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Moderna, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Moderna, Inc., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for MRNA: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
The reconstruction
The price sits 14% above the median analyst target and at the 77th percentile of published models, meaning the market has already paid for a bullish outcome that most bearish models reject.
What the disagreement turns on
Whether the mRNA oncology platform can convert positive Phase 3 melanoma data into a multi-billion-dollar commercial franchise before the company's cash reserves deplete, a question that available wired data cannot settle.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $137 on 2026-09-11 — the quote has since moved +13%, so read this as a record of what was priced in then, not now.
